journal
https://read.qxmd.com/read/38227596/virological-weight-and-drug-resistance-outcomes-among-patients-initiating-a-dolutegravir-based-first-line-antiretroviral-therapy-regimen-in-zimbabwe
#61
JOURNAL ARTICLE
Vinie Kouamou, Tendai Washaya, Tichaona Mapangisana, Chiratidzo Ellen Ndhlovu, Justen Manasa
OBJECTIVE: Dolutegravir (DTG)-based antiretroviral therapy (ART) is being scaled up in Africa. However, clinical experience with DTG and patterns of HIV drug resistance (HIVDR) are sparse in Zimbabwe. We assessed virological, weight, and HIVDR outcomes among individuals initiating on a DTG-based ART. DESIGN: We conducted a prospective cohort study among HIV-infected adult (≥18 years old) individuals attending care at Parirenyatwa hospital, Harare, Zimbabwe between October 2021 and April 2023...
April 1, 2024: AIDS
https://read.qxmd.com/read/38126353/optimizing-behavioral-and-pharmacological-smoking-cessation-interventions-among-people-with-hiv
#62
RANDOMIZED CONTROLLED TRIAL
Seth Himelhoch, Deana Kelly, Chris deFilippi, Gregory Taylor, Melanie Bennett, Deborah Medoff, Lan Li, Robert Christenson, Wendy Potts, Jonathan Shuter
BACKGROUND: People with HIV/AIDS (PWH) smoke at nearly three times the rate of the general population. Interventions to promote sustained quitting among PWH are urgently needed. METHODS: Our study used a randomized factorial design to evaluate the effects of varenicline, compared with placebo, and behavioral cessation therapy, positively smoke free (PSF), compared with standard of care (SOC) among PWH who smoke. The study was designed with power to detect a small effect (Cohen's h of 0...
April 1, 2024: AIDS
https://read.qxmd.com/read/38416557/authors-response-to-optimizing-behavioral-and-pharmacological-smoking-cessation-interventions-among-people-with-hiv-comment
#63
JOURNAL ARTICLE
Seth S Himelhoch, Jonathan Shuter
No abstract text is available yet for this article.
March 15, 2024: AIDS
https://read.qxmd.com/read/38416556/optimizing-behavioral-and-pharmacological-smoking-cessation-interventions-among-people-with-hiv-comment
#64
JOURNAL ARTICLE
Hinpetch Daungsupawong, Viroj Wiwanitkit
No abstract text is available yet for this article.
March 15, 2024: AIDS
https://read.qxmd.com/read/38416555/trends-in-hiv-preexposure-prophylaxis-utilization-and-spending-among-individuals-with-commercial-insurance
#65
JOURNAL ARTICLE
Sean Dickson, Katelyn James
In a cross-sectional analysis of HIV preexposure prophylaxis (PrEP) utilization by commercially insured patients from 2019 to 2021, most prescriptions were for branded formulations of PrEP despite the availability of a generic version. Accounting for the modest relative clinical benefit of branded TAF/FTC (tenofovir alafenamide fumarate/emtricitabine) PrEP over generic TDF/FTC (tenofovir disoproxil fumarate/emtricitabine) PrEP, use of generic TDF/FTC PrEP would have reduced commercial insurers' spending by 33%...
March 15, 2024: AIDS
https://read.qxmd.com/read/38416554/hiv-1-envelope-diversity-and-sensitivity-to-broadly-neutralizing-antibodies-across-stages-of-acute-hiv-1-infection
#66
JOURNAL ARTICLE
Laurie A VanderVeen, Lisa Selzer, Brian Moldt, Aiyappa Parvangada, Jiani Li, Jintanat Ananworanich, Trevor A Crowell, Joseph J Eron, Eric S Daar, Richard Haubrich, Romas Geleziunas, Joshua Cyktor, John W Mellors, Christian Callebaut
We studied the relationship between viral diversity and susceptibility to broadly neutralizing antibodies (bNAbs) in longitudinal plasma and peripheral blood mononuclear cells from 89 people with HIV who initiated antiretroviral therapy (ART) during acute and early HIV-1 infection (AEHI). HIV-1 diversity and predicted bNAb susceptibility were comparable across AEHI. Diversity evolution was not observed during ART, suggesting (pro)viruses at initiation or during treatment may identify individuals with susceptible virus for bNAb interventional trials...
March 15, 2024: AIDS
https://read.qxmd.com/read/38416553/is-the-glp-1-receptor-agonist-semaglutide-a-good-option-for-weight-loss-in-persons-with-hiv
#67
JOURNAL ARTICLE
Daniel Lee, Jacqueline Capeau
No abstract text is available yet for this article.
March 15, 2024: AIDS
https://read.qxmd.com/read/38416552/reassessing-the-emphasis-on-limited-options-in-antiretroviral-treatment
#68
EDITORIAL
Mauro Zaccarelli
No abstract text is available yet for this article.
March 15, 2024: AIDS
https://read.qxmd.com/read/38416551/could-humoral-immune-responses-to-herpesviruses-be-a-pathogenic-driver-of-cognitive-disorders-in-persons-with-hiv
#69
JOURNAL ARTICLE
Alan Winston, Patricia Price
No abstract text is available yet for this article.
March 15, 2024: AIDS
https://read.qxmd.com/read/38416550/a-new-frontier-in-hiv-care-the-predictive-power-of-renal-biomarkers-on-heart-health
#70
EDITORIAL
Silvia Mascolo, Antonio Romanelli
No abstract text is available yet for this article.
March 15, 2024: AIDS
https://read.qxmd.com/read/38061030/bone-turnover-change-after-randomized-switch-from-tenofovir-disoproxil-to-tenofovir-alafenamide-fumarate-in-men-with-hiv
#71
RANDOMIZED CONTROLLED TRIAL
Amelia E B Moore, James E Burns, Deirdre Sally, Ana Milinkovic, Georgios Krokos, Joemon John, Christopher Rookyard, Alessandro Borca, Erica R M Pool, Anna Tostevin, Alyss Harman, Dwight S Dulnoan, Richard Gilson, Alejandro Arenas-Pinto, Gary J R Cook, John Saunders, David Dunn, Glen M Blake, Sarah L Pett
OBJECTIVE: Bone loss in people with HIV (PWH) is poorly understood. Switching tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) has yielded bone mineral density (BMD) increases. PETRAM (NCT#:03405012) investigated whether BMD and bone turnover changes correlate. DESIGN: Open-label, randomized controlled trial. SETTING: Single-site, outpatient, secondary care. PARTICIPANTS: Nonosteoporotic, virologically suppressed, cis-male PWH taking TDF/emtricitabine (FTC)/rilpivirine (RPV) for more than 24 weeks...
March 15, 2024: AIDS
https://read.qxmd.com/read/38300163/lower-aids-related-hospitalizations-in-women-living-with-hiv-multidrug-resistance
#72
JOURNAL ARTICLE
Rebecka Papaioannu Borjesson, Laura Galli, Riccardo Lolatto, Barbara Menzaghi, Marcello Feasi, Roberto Gulminetti, Chiara Fornabaio, Anna Maria Cattelan, Stefano Bonora, Filippo Lagi, Maurizio Zazzi, Antonella Castagna, Vincenzo Spagnuolo
No abstract text is available yet for this article.
March 1, 2024: AIDS
https://read.qxmd.com/read/38300162/people-with-hiv-pioneers-of-injectable-cabotegravir-and-rilpivirine-long-acting-in-italy-who-are-they
#73
MULTICENTER STUDY
Claudia Bartalucci, Federico Baldi, Elena Ricci, Giancarlo Orofino, Barbara Menzaghi, Sergio Ferrara, Giovanni Francesco Pellicano', Nicola Squillace, Eleonora Sarchi, Emanuele Pontali, Giovanni Cenderello, Olivia Bargiacchi, Matteo Piccica, Maria Aurora Carleo, Antonio Cascio, Giuseppe Vittorio De Socio, Paolo Bonfanti, Antonio Di Biagio
Injectable cabotegravir and rilpivirine long-acting therapy is a revolutionary new antiretroviral treatment (ART) option for HIV infection in virologically suppressed adults on a stable ART. The aim of this study from SCOLTA multicenter observational prospective database is to describe the first people living with HIV (PWH) who started this regimen in Italy, assessing adherence to eligibility criteria, describing clinical-epidemiological characteristics compared to registration trials-population and describe early treatment-discontinuations...
March 1, 2024: AIDS
https://read.qxmd.com/read/38300161/criteria-for-classification-nomenclature-and-reference-sequence-selection-for-hiv-sub-subtypes-of-crf01_ae-and-crf07_bc-strains-in-china
#74
JOURNAL ARTICLE
Dong Wang, Yi Feng, Yuhua Ruan, Lingjie Liao, Jingjing Hao, Chang Song, Jing Hu, Yiming Shao, Hui Xing
The available knowledge regarding classification, nomenclature, and reference sequence selection for the various sub-subtypes of circulating recombinant forms (CRFs) is inadequate to fulfill the growing demands of research focused on HIV prevention. We analyzed the spread of CRF01_AE and CRF07_BC strains, mainly in China, to complement and update the existing nomenclature and to propose a reference sequence selection criteria for sub-subtypes of CRFs.
March 1, 2024: AIDS
https://read.qxmd.com/read/38300160/early-adopters-of-long-acting-injectable-cabotegravir-rilpivirine-what-lessons-can-we-learn
#75
JOURNAL ARTICLE
Brian R Wood, Nagalingeswaran Kumarasamy
No abstract text is available yet for this article.
March 1, 2024: AIDS
https://read.qxmd.com/read/38300159/antiretroviral-therapy-prescribing-in-the-real-world-and-impact-on-cancer-risk
#76
JOURNAL ARTICLE
Ramya Ramaswami
No abstract text is available yet for this article.
March 1, 2024: AIDS
https://read.qxmd.com/read/38300158/elimination-of-perinatal-transmission-of-hepatitis-b-lessons-learned-from-women-with-hiv-hbv-coinfection
#77
JOURNAL ARTICLE
Patricia M Flynn, Sanjay Bhagani
No abstract text is available yet for this article.
March 1, 2024: AIDS
https://read.qxmd.com/read/38300157/sexual-behaviours-and-risk-with-women-in-msm-in-sub-saharan-africa
#78
JOURNAL ARTICLE
Marion Fiorentino, Nathan Yanwou, Robinson Gravier-Dumonceau Mazelier, August Eubanks, Perrine Roux, Christian Laurent, Bruno Spire
In sub-Saharan Africa (SSA), MSM - a high HIV prevalence group - experience strong social stigma and pressure to have female partners. Accordingly, they could constitute a bridging group for HIV transmission to cisgender women. We developed a multilevel summary of MSM sexual behaviors and risk with women in various SSA regions. Following PRISMA guidelines, we conducted a mixed-method systematic review of data of sex with women in MSM in SSA. We performed meta-analyses on quantitative data (i.e. percent of recent sex and condomless sex with women) for each SSA region (when proportions reported in ≥4 studies)...
March 1, 2024: AIDS
https://read.qxmd.com/read/37916464/cerebrospinal-fluid-pleocytosis-is-associated-with-hiv-1-neuroinvasion-during-acute-infection
#79
JOURNAL ARTICLE
Phillip Chan, Sarah Moreland, Carlo Sacdalan, Eugene Kroon, Donn Colby, Somchai Sriplienchan, Suteeraporn Pinyakorn, Nittaya Phanuphak, Linda Jagodzinski, Victor Valcour, Sandhya Vasan, Robert Paul, Lydie Trautmann, Serena Spudich
OBJECTIVE: HIV-1 invades the brain within days post-transmission. This study quantitated cerebrospinal fluid (CSF) white blood cell count (WBC) and investigated whether it associated with plasma and CSF HIV-1 RNA during untreated acute HIV infection (AHI). DESIGN: Seventy participants underwent lumbar puncture during Fiebig stages I-V AHI. METHOD: WBC and HIV-1 RNA with a lower limit of quantification (LLQ) of 80 copies/ml were measured in CSF...
March 1, 2024: AIDS
https://read.qxmd.com/read/37890463/real-world-use-of-antiretroviral-therapy-and-risk-of-cancer-among-people-with-hiv-in-texas
#80
JOURNAL ARTICLE
Marie-Josephe Horner, Meredith S Shiels, Timothy S McNeel, Analise Monterosso, Paige Miller, Ruth M Pfeiffer, Eric A Engels
BACKGROUND: Combination antiretroviral therapy (cART) may reduce cancer risk among people with HIV (PWH), but cancer-specific associations are incompletely understood. METHODS: We linked HIV and cancer registries in Texas to a national prescription claims database. cART use was quantified as the proportion of days covered (PDC). Cox proportional hazards models assessed associations of cancer risk with cART usage, adjusting for demographic characteristics, AIDS status, and time since HIV report...
March 1, 2024: AIDS
journal
journal
20006
4
5
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.